IP Library › Granted Patent US 12,274,694
Granted Patent B2
US 12,274,694 · App. 18/296,543 · Granted Apr 15, 2025

Dizocilpine derivatives as peripheral NMDA receptor antagonists

Inventors: Sylvia Cohen-Kaminsky (Le Plessis-Robinson, FR); Marc Humbert (Le Plessis-Robinson, FR); Sebastien Dumas (Le Plessis-Robinson, FR); Gilles Bru-Mercier (Le Plessis-Robinson, FR); Samir Messaoudi (Chatenay-Malabry, FR); Jean-Daniel Brion (Chatenay-Malabry, FR); Mouad Alami (Chatenay-Malabry, FR); Gilles Galvani (Chatenay-Malabry, FR)
Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITÉ PARIS-SACLAY; ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP); HOPITAL MARIE LANNELONGUE
A61K31/46A61K45/06A61P9/12C07D451/00C07D451/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,694
App. No.
18/296,543
Granted
Apr 15, 2025
Kind
B2
Abstract

The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Claims (16)

1. A compound selected from the group consisting of the following compounds:

2. A pharmaceutical composition, comprising:

at least one compound of claim 1 , and

at least one pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 , further comprising at least one other therapeutic agent.

4. The pharmaceutical composition of claim 2 , further comprising at least one other therapeutic agent selected from the group consisting of a vasodilator agent and a glutamate receptor antagonist, wherein the glutamate receptor antagonist is ionotropic and/or metabotropic.

5. The pharmaceutical composition of claim 2 , further comprising at least one other therapeutic agent selected from the group consisting of NMDAR antagonists.

6. A method for treating a disease or condition in a subject, the method comprising:

administering the compound of claim 1 to the subject,

wherein the disease or condition is pulmonary hypertension.

7. A method for treating a disease or condition in a subject, the method comprising:

administering the compound of the claim 1 to the subject,

wherein the disease or condition is selected from the group consisting of pulmonary arterial hypertension and thromboembolic pulmonary hypertension.

8. A method for treating a disease in a subject, the method comprising:

administering the compound of claim 1 the subject,

wherein the disease is pulmonary arterial hypertension.

Priority Claims (1)
EP 16305712 · Jun 13, 2016 · regional
Continuity (3)
Division 17825082 · May 26, 2022
Division 16308654
Related Publication 20230285381A1 · Sep 14, 2023
References Cited (20)
US 4888347A · Woodruff · 1989 [cited by examiner]
US 11376245B2 · Cohen-Kaminsky · 2022 [cited by examiner]
International Search Report issued Jul. 12, 2017 in PCT/EP2017/064409, 3 pages. [cited by applicant]
European Search Report issued Dec. 2, 2016 in Patent Application No. 16305712, 2 pages. [cited by applicant]
Linders, J.T.M. et al. “Synthesis and Preliminary Biochemical Evaluation of Novel Derivatives of PCP” Letters in Drug Design and Discovery, vol. 7, No. 2, XP009192463, 2010, pp. 79-87. [cited by applicant]
Thompson, W.J. et al. “Synthesis and Pharmacological Evaluation of a Series of Dibenzo[a, d]cycloalkenimines as N-Methyl-D-aspartate Antagonists” Journal of Medicinal Chemistry, American Chemical Society, vol. 33, No. 2… [cited by applicant]
Memezawa, H. et al. “Hyperthermia nullifies the ameliorating effect of dizocilpine maleate (MK-801) in focal cerebral ischemia” Brain Research, Elsevier, vol. 670, No. 1, XP022256910, 1995, pp. 48-52. [cited by applicant]
Nagpal et al., “Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB”, Expert Opin. Drug Deliv., vol. 10, 30 pages, Jan. 2013. [cited by applicant]
Doran et al., “The Impact of P-Glycoprotein on the Disposition of Drugs Targeted for Indications of the Central Nervous System: Evaluation Using the MDR1A/1B Knockout Mouse Model”, Drug Metabolism and Disposition, vol. … [cited by applicant]
Office Action issued Aug. 12, 2021 in Chinese Patent Application No. 201780049508.2, filed Jun. 13, 2017, 13 pages (with English Translation). [cited by applicant]
Pearce et al., “Failure modes, etc.,” Cancer Drug Design and Discovery, ed. Stephen Neidle, Chapter 18, pp. 424-435. (Year: 2008). [cited by applicant]
Jordan, V.C., “Tamoxifen: A Most, etc.,” Nature review: Drug Discovery, 2, 205-213. (Year: 2003). [cited by applicant]
Simone, Oncology: Introduction, Cecil Textbook of Medicine, ed Bennett et al. W.B. Saunders CO 20th ed, vol. 1, pp. 1004-1010 ( Year: 1996). [cited by applicant]
Gura, Systems for Identifying New Drugs Are Often Faulty, Cancer Models, Science, 278(5340), pp. 1041-1042. (Year: 1997). [cited by applicant]
Johnson et al., Relationships between drug activity in NCI in vitro and in vivo and early clinical trials, British Journal of Cancer 64(10): 1424-1431. (Year: 2001). [cited by applicant]
Hanada, “Ionotrophic Glutamate, etc.,” Biomolecules, 20, 464, 1-22. (Year: 2020). [cited by applicant]
Ahmed et al., “N-Methyl-D-Aspartate, etc.,” Expert Opinion on Therapeutic Patents, 30(10), 743-767. (Year: 2020). [cited by applicant]
Capuco et al., “A Comprehensive, etc.,” Current Pain and Headache Reports 24:41, 1-12. (Year: 2020). [cited by applicant]
Hayashi et al., “Effects of neural, etc.,” Journal of Biomedical Science, 27:29, 1-11. (Year: 2020). [cited by applicant]
Kreutzwiser et al., “Expanding Role of NMDA, etc.,” CNS Drugs, 33, 347-374. (Year: 2019). [cited by applicant]